vascular normalization rgs5-deficient tumours promotes immune destruction 
vasculature solid tumours morphologically aberrant characterized dilated fragile vessels intensive vessel sprouting loss hierarchical architecture constant vessel remodelling leads spontaneous haemorrhages increased interstitial fluid pressure tumour environment tumour-related angiogenesis supports tumour growth also major obstacle successful immune therapy prevents migration immune effector cells established tumour parenchyma molecular mechanisms angiogenic alterations largely unknown identify regulator g-protein signalling rgs5 master gene responsible abnormal tumour vascular morphology mice loss rgs5 results pericyte maturation vascular normalization consequent marked reductions tumour hypoxia vessel leakiness vascular intratumoral changes enhance influx immune effector cells tumour parenchyma markedly prolong survival tumour-bearing mice first demonstration knowledge reduced tumour angiogenesis improved immune therapeutic outcome loss vascular gene function establishes previously unrecognized role g-protein signalling tumour angiogenesis 
